SCHEMBL23498486

SCHEMBL23498486

O=C(O)N(Cc1ccco1)c1nc(Cl)nc2ccsc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 6/20 0.42
ALDH1A1 P00352 5/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
MAPT P10636 3/20 0.42
LMNA P02545 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
TP53 P04637 1/20 0.41
POLB P06746 2/20 0.41
MAPK1 P28482 3/20 0.40
UBE2N P61088 1/20 0.40
PDK1 Q15118 1/20 0.40
NPC1 O15118 1/20 0.40
AGTR1 P30556 1/20 0.40
HPGD P15428 1/20 0.40
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29997949 0.86 TP53 (0.39) TSHRALDH1A1MEN1KMT2AMAPT
SCHEMBL25066131 0.86 TP53 (0.39) TSHRALDH1A1MEN1KMT2AMAPT
SCHEMBL23498686 0.80 LMNA (0.43) TSHRALDH1A1MEN1KMT2AMAPT
SCHEMBL23498695 0.79 MEN1 (0.44) TSHRALDH1A1MEN1KMT2AMAPT
SCHEMBL23498859 0.78 TSHR (0.45) TSHRALDH1A1MEN1KMT2AMAPT
SCHEMBL23498508 0.75 ALDH1A1 (0.40) TSHRALDH1A1MEN1KMT2AMAPT
SCHEMBL23498461 0.74 LMNA (0.39) TSHRALDH1A1MEN1KMT2AMAPT
SCHEMBL23498563 0.72 MAPT (0.51) TSHRALDH1A1MEN1KMT2AMAPT
SCHEMBL23498488 0.71 HSD17B10 (0.50) TSHRALDH1A1MEN1KMT2AMAPT
SCHEMBL6859721 0.71 ADORA2A (0.68) ALDH1A1KMT2AMAPTPOLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230057568-A1 COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA PTC THERAPEUTICS, INC. (US) 2023-02-23 US disclosed
WO-2021118929-A1 COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA PTC THERAPEUTICS, INC. (US) 2021-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230057568-A1 COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA SNRPB2, SYNCRIP, HNRNPUL2 TSHR 2908/4885ALDH1A1 2146/4885MEN1 1139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.